Medicare Part D Coverage and Costs for Glucagon-Like Peptide-1 Receptor Agonists

Key Points

• This analysis reveals disparities in Medicare Part D coverage and out-of-pocket costs for GLP-1 receptor agonists.
• Findings indicate significant variability in costs affecting patient access to glucagon-like peptide-1 receptor agonists.
• The cross-sectional study analyzes data post-Inflation Reduction Act implementation, providing insights into coverage changes.
• These insights highlight the importance of policy impacts on medication accessibility for patients with diabetes.